ProCE Banner Activity

EMPEROR-Preserved: Primary Endpoint and Key Quality of Life Results With Empagliflozin vs Placebo in Patients With LVEF ≥50%

Slideset Download
Conference Coverage
Significant improvement vs placebo in composite primary endpoint even in patients with “true” HFpEF.

Released: December 02, 2021

Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by an educational grant from